JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

Home・Aktien・Cogent Biosciences Inc

Cogent Biosciences Inc

Geschlossen

36.95 3.85

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

36.07

Max

37.32

Schlüsselkennzahlen
By Trading Economics
Einkommen	-7.4M -81M
EPS	-0.5
Angestellte	205
EBITDA	-6.8M -79M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+40.98% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	24. Feb. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	3.7B 5.8B
Vorheriger Eröffnungskurs	33.1
Vorheriger Schlusskurs	36.95

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

4.88 / 5.87 Unterstützung & Widerstand

Cogent Biosciences Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

6. Feb. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

6. Feb. 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

6. Feb. 2026, 21:40 UTC

Akquisitionen, Fusionen, Übernahmen

Verizon Insiders Rarely Sell Company Stock. This Insider Just Did. -- Barrons.com

6. Feb. 2026, 21:22 UTC

Market Talk

Mexico's Inflation Seen Accelerating in January -- Market Talk

6. Feb. 2026, 21:17 UTC

Ergebnisse

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

6. Feb. 2026, 21:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6. Feb. 2026, 21:14 UTC

Akquisitionen, Fusionen, Übernahmen

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- Update

6. Feb. 2026, 21:13 UTC

Ergebnisse

How the Software Panic Hit BDC Stocks -- and Why Some Might Be Worth Buying -- Barrons.com

6. Feb. 2026, 21:13 UTC

Ergebnisse

Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More Stock Market Movers -- Barrons.com

6. Feb. 2026, 21:04 UTC

Market Talk

Gold Closes Out Volatile Week on Higher Note -- Market Talk

6. Feb. 2026, 20:34 UTC

Ergebnisse

Tech Had an Awful Earnings Season. Other Stocks Are Saving the Day. -- Barrons.com

6. Feb. 2026, 20:27 UTC

Ergebnisse

These Stocks Are Today's Movers: Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More -- Barrons.com

6. Feb. 2026, 20:24 UTC

Market Talk

Oil Futures Settle Higher As U.S.-Iran Talks Get Under Way -- Market Talk

6. Feb. 2026, 20:20 UTC

Market Talk

U.S. Natural Gas Futures Retreat Ahead of Weekend -- Market Talk

6. Feb. 2026, 19:48 UTC

Ergebnisse

Take-Two, Mondelez Get Analyst Attention -- Barrons.com

6. Feb. 2026, 19:30 UTC

Akquisitionen, Fusionen, Übernahmen

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- WSJ

6. Feb. 2026, 19:30 UTC

Akquisitionen, Fusionen, Übernahmen

Justice Department Asking Industry How Netflix or Paramount Deal for Warner Bros. Might Impact Competition, According to Subpoena -- WSJ

6. Feb. 2026, 19:30 UTC

Akquisitionen, Fusionen, Übernahmen

DOJ Asking if Netflix Engaged in 'Exclusionary Conduct' That May Lead to Monopoly, According to Subpoena -- WSJ

6. Feb. 2026, 19:17 UTC

Market Talk

USDA Says Farm Income to Decrease in 2026 -- Market Talk

6. Feb. 2026, 18:50 UTC

Ergebnisse

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

6. Feb. 2026, 18:47 UTC

Market Talk

Natural Gas-Infrastructure Operators Take 'Flight to Scale' -- Market Talk

6. Feb. 2026, 18:34 UTC

Market Talk

U.S. Oil Rig Count Rises By 1 to 412 -- Market Talk

6. Feb. 2026, 17:58 UTC

Ergebnisse

Reddit Stock Falls After Strong Earnings. Wall Street Is Debating What's Next. -- Barrons.com

6. Feb. 2026, 17:52 UTC

Market Talk

Ergebnisse

Global Equities Roundup: Market Talk

6. Feb. 2026, 17:52 UTC

Market Talk

Ergebnisse

Amazon's CapEx Seen as Misunderstood by Investors -- Market Talk

6. Feb. 2026, 17:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

6. Feb. 2026, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

6. Feb. 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

6. Feb. 2026, 17:18 UTC

Market Talk

Canada's Bizarre Jobs Report Points to Growing Labor Slack -- Market Talk

6. Feb. 2026, 17:09 UTC

Market Talk

Dollar on Path to Snap Weekly Losing Streak -- Market Talk

Peer-Vergleich

Kursveränderung

Cogent Biosciences Inc Prognose

Kursziel

By TipRanks

40.98% Vorteil

12-Monats-Prognose

Durchschnitt 50.33 USD 40.98%

Hoch 67 USD

Tief 34 USD

Basierend auf 13 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Cogent Biosciences Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

13 ratings

Buy

Halten

Sell

Basierend auf 13 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Cogent Biosciences Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

4.88 / 5.87Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.